What if you bought Celltrion at its COVID-treatment hype peak?
This uses real data to show what would have happened if you had invested a lump sum in Celltrion (068270) in early December 2020 — near its record high amid the 2020 biotech frenzy over a COVID antibody treatment. We honestly examine the result of buying at the peak of theme excitement.
⚠️ Know the risk first
News of the treatment did not immediately translate into gains, and anyone buying near the peak had to endure a long correction. Always review the maximum drawdown and loss periods.
⚠️ This asset is an individual stock chosen as of today, so past returns can look better than they really were (survivorship bias).
What happened that day
In late 2020, Celltrion soared to around 300,000 won near its record high on hopes around its COVID antibody treatment CT-P59 (Regkirona) and its Korean approval filing. But it took time for the treatment to translate into revenue, and as the biotech theme cooled, the stock underwent a long correction.
Why this date
The buy point is near the record high when biotech theme excitement peaked, computing the question 'what if you bought at the top of the theme frenzy.'
Investment conditions
Asset · Celltrion (068270) · lump-sum near the 2020 biotech-frenzy high, then held long-term
Method · Lump-sum (all at once)
Period · 2020-12-07 ~ 2026-07-01
Amount · $7,407
As of · 2026-07-01
Key metrics
These results do not reflect taxes. Based on historical data.
Buy and final prices are shown in the asset's local currency (US & crypto $, Japan ¥, Korea ₩). Total invested and final value are in Korean won (₩).
Risk & recovery
As important as returns. This service does not hide maximum drawdown or loss periods.
Maximum drawdown (MDD)
-64.5%
Largest drop from peak
Longest loss period
68months
Months in loss: 68
Recovery period
0months
Growth over time
Invested principal (dashed) and portfolio value (solid). Values below match the calculation.
Total invested $7,407 → Final value $4,040 (-45.5%), Maximum drawdown (MDD) -64.5%
Why this period and asset
Late 2020 was a period of extreme enthusiasm for biotech and pharma stocks amid COVID. On news of its COVID antibody treatment CT-P59 (Regkirona), Celltrion soared to around 300,000 won, near its record high, with excitement peaking ahead of its Korean approval filing in late December 2020. But it took time for the treatment to translate into actual revenue, and as the biotech theme cooled, the stock underwent a long correction. (Note: this company later went through a 2023 merger with Celltrion Healthcare and others; adjusted close reflects such events.)
Interpreting the result
If you bought near the peak when theme excitement was hottest and never sold, check the final value and return in the metrics below. The key is 'how long it took to recover the price you paid at the peak of hype.' See — alongside the maximum drawdown and loss periods — that news of a hyped treatment did not immediately translate into stock gains. Investing gradually each month instead of all at once would have reduced the risk of concentrating your buy at a peak.
Caveats & limits
'Buying at the peak of theme excitement' is a classic peak-buying situation. Emphasizing only the final return hides the long correction and loss period that followed. As a single stock, be mindful of survivorship bias. Celltrion has a merger/relisting history, so care is needed when comparing long-term prices; figures use adjusted close and exclude fees and taxes (pre-tax). Past results do not guarantee the future.
Event fact sources
- Korea Herald — Celltrion's COVID-19 antibody treatment applies for use in Korea (2020-12-29)
- Investing.com — Celltrion Reports Positive Results for COVID-19 antibody CT-P59 (2020)
Requested date vs actual trading date
If the event date is a holiday, the fill uses the next trading day's close. The 'effective trading date' below is the date actually used.
Data sources & limits
- Price data source: Yahoo Finance / FinanceDataReader
- Collected on: 2026-07-28
- Effective trading date: 2026-07-01
- Price basis: Adjusted close (reflects dividends and stock splits)
- This asset is an individual stock chosen as of today, so past returns can look better than they really were (survivorship bias).
- Trading fees and taxes are not reflected — figures are pre-tax.
- Based on historical data; does not guarantee future returns.
Frequently asked questions
Was Celltrion really near its record high then?
Yes. In late 2020, on hopes around its COVID antibody treatment CT-P59 and its approval filing, Celltrion rose to around 300,000 won, near its record high. It was the peak of biotech theme excitement.
There was treatment news — why did the stock struggle afterward?
Buzz and actual earnings are separate things. It took time for the treatment to translate into revenue, and as the biotech theme cooled, anyone who bought near the peak had to endure a long correction. Check the maximum drawdown and loss periods below.
It has a merger/relisting history — is the calculation still valid?
Celltrion went through a 2023 affiliate merger, and this service uses adjusted close to reflect such events as much as possible. Still, note that such structural changes occurred when comparing long-term prices.
Are FX and taxes reflected?
This is a Korean stock shown in won, so there is no exchange-rate variable. Trading fees and taxes are not reflected (pre-tax). This page only shows historical data and recommends no specific stock.
Related scenarios
📋 Results are based on historical data; past returns do not guarantee future returns.
📋 This service is provided for educational purposes to help you understand investing, not as investment advice.
⚠️ Calculated using today's representative assets, which may differ from the market composition at the time.